Drug intelligence / Profile preview

mecbotamab vedotin + nivolumab

Development stage: Unknown
Lead developer: BioAtla
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Mecbotamab vedotin + nivolumab is a combination therapy being investigated for the treatment of solid tumors, particularly non-small cell lung cancer (NSCLC) and sarcomas. Mecbotamab vedotin (BA3011) is a conditionally and reversibly active antibody drug conjugate (CAB-AXL-ADC) targeting the receptor tyrosine kinase AXL. Nivolumab is a PD-1 inhibitor. The combination is being studied in patients who have previously progressed on PD-1/L1, EGFR or ALK inhibitor therapies.

Targets

PDCD1 (Programmed cell death protein 1 receptor)AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on mecbotamab vedotin + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mecbotamab vedotin + nivolumab.

Explore the full profile